20 completed, 12 recruiting, 7 unknown, 5 terminated. 55 Phase 2, 12 Phase 1.
Follow neratinib: new trials by email Literature Review of neratinib trials Research Report on neratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis Neratinib, Trastuzumab Deruxtecan - Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer | Phase 2 | Recruiting | Fudan University | 202 | 2025-09-24 | 2026-09-28 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor Fulvestrant, Neratinib, Alpelisib - Advanced Breast Cancer | Phase 2 | Recruiting | Dartmouth-Hitchcock Medical Center | 135 | 2024-09-23 | 2026-01-20 |
| Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations Neratinib tablets - Advanced Solid Tumor | Phase 2 | Unknown | Convalife (Shanghai) Co., Ltd. | 60 | 2024-08-10 | 2024-07-25 |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Endocrine Therapy, Biopsy of breast, Neratinib - Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2024-06-11 | 2026-08-19 |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-05-07 | 2026-11-05 |
| Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases Neratinib maleate in combination with capecitabine - Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis | Phase 2 | Not yet recruiting | Convalife (Shanghai) Co., Ltd. | 28 | 2024-04-30 | 2024-04-19 |
| Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer Neratinib, Trastuzumab, Oxaliplatin - GastroEsophageal Cancer, Gastric Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 8 | 2024-01-12 | 2026-06-12 |
| Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations Neratinib tablets - NSCLC | Phase 2 | Unknown | Convalife (Shanghai) Co., Ltd. | 42 | 2023-11-20 | 2023-09-08 |
| Fulvestrant + Neratinib In Breast Cancer NERATINIB, FULVESTRANT - Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2023-07-01 | 2023-08-01 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-12 |
| Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease Neratinib - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 15 | 2022-12-06 | 2026-10-13 |
| Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling Capecitabine and Neratinib. - Breast Cancer | Phase 2 | Recruiting | University of Rochester | 22 | 2022-09-23 | 2025-12-15 |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Neratinib, Loperamide, Colesevelam - Early-stage Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Active not recruiting | Spanish Breast Cancer Research Group | 177 | 2022-08-31 | 2025-04-01 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2022-08-18 | 2025-06-11 |
| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Ruth O'Regan | 30 | 2022-07-21 | 2026-09-03 |
| Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer Neratinib - HER2-positive Breast Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 60 | 2022-01-01 | 2021-12-13 |
| Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer Neratinib - Breast Cancer, Brain Metastases | Phase 2 | Withdrawn | Jules Bordet Institute | 2021-11-24 | 2022-03-02 |
Showing 20 of 55. Sign in to see all of them.
Breast Neoplasms (29) · Neoplasm Metastasis (7) · Brain Neoplasms (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Carcinoma, Lobular (1) · Carcinoma, Pancreatic Ductal (1) · Central Nervous System Neoplasms (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Disease (1)
Puma Biotechnology, Inc. (13) · NSABP Foundation Inc (4) · Convalife (Shanghai) Co., Ltd. (3) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · University Health Network, Toronto (2) · Beth Israel Deaconess Medical Center (1) · Chinese Academy of Medical Sciences (1) · City of Hope Medical Center (1) · Dartmouth-Hitchcock Medical Center (1) · David Reardon, MD (1) · Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (40) · Spain (11) · Canada (10) · France (10) · China (9) · Belgium (6) · Hong Kong (6) · South Korea (6) · United Kingdom (6) · Australia (5) · Poland (5) · Hungary (4) · Italy (4) · Puerto Rico (4) · Croatia (3)
Norman Wolmark, MD (4) · Aditya Bardia, MD,MPH (1) · Ajay Dhakal (1) · Andrew Poklepovic, MD (1) · Asona Lui, MD, PhD (1) · Chau Dang, MD (1) · Cynthia Ma, M.D., Ph.D (1) · Dae Won Kim, MD (1) · David Einstein, MD (1) · David Y Reardon, MD (1) · Gregory A Vidal, MD.,PhD (1) · Haider S Mahdi (1)
PMID 35181666, PMID 37597578, PMID 41193346, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 22967996, PMID 23632474, PMID 23953056, PMID 24077916, PMID 25287822, PMID 26834058, PMID 27078022, PMID 27406346, PMID 27406347, PMID 27713176, PMID 28274957, PMID 28302091, PMID 28851423, PMID 30860945, PMID 31442103, PMID 31548342, PMID 31558424, PMID 31796073, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32464281, PMID 32701140, PMID 32723675, PMID 32919527, PMID 32923853, PMID 33203645, PMID 33663941, PMID 33796451, PMID 33893289, PMID 34482636, PMID 34529000, PMID 34741021, PMID 35575067, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 36702070, PMID 36746967, PMID 37029329, PMID 37325931, PMID 37505107
2019 (3), 2015 (1), K12CA001727 (1), P30CA033572 (1), R01CA273246 (1), U10CA180820 (1), U10CA180868 (1)